cenicriviroc

Indications

• investigational drug candidate for
  • treatment of HIV1 infection
  • in combination with Tropifexor for non-alcoholic steatohepatitis

Contraindications

• does not reduce recovery time in hospitalized patients with Covid-19 pneumonia
  • may have small mortality benefit
    • all-cause 28-day mortality
      • 13.8% for cenicriviroc vs 11.9% for placebo

Dosage

• loading dose 300 mg PO
  • 150 mg PO BID

Mechanism of action

• orally active dual inhibitor of CC chemokine receptor 2 (CCR2) & CCR5
• cenicriviroc inhibits HIV-1 & HIV-2
• potent anti-inflammatory & antiinfective activity

More general terms

• receptor antagonist
• antiviral agent
• gastrointestinal agent
• heterocyclic compound, 2 rings
• aromatic compound